diabetes
Sanofi’s new diabetes device: worth the price?
March 12, 2012Medical Communications NHS, Sanofi, app, diabetes, iBGStar, smartphone
Sanofi launched its new iPhone and iPod Touch blood sugar monitor to much fanfare this week, but its high price …
Sanofi launches iPhone and iPod glucose monitor in the UK
March 12, 2012Medical Communications, Sales and Marketing BGStar, Sanofi, diabetes, iPod, iphone
Sanofi has launched a new diabetes device in the UK to help patients monitor their blood sugar levels from their …
Diabetes – the battle for control
February 15, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Novo Nordisk, Sanofi, Victoza, degludec, diabetes
This year marks the 90th anniversary of the first ever successful use of insulin to treat patients with type I …
AZ and BMS diabetes drug needs more data
January 20, 2012Research and Development, Sales and Marketing AstraZeneca, BMS, FDA approvals, diabetes
AstraZeneca and Bristol-Myers Squibb must supply more data on their diabetes treatment dapagliflozin, the FDA says.Currently being developed as monotherapy, …
Sanofi to collaborate with UCSF on diabetes research
January 11, 2012Research and Development RNA interference, Sanofi, UCSF, academic alliance, diabetes
The University of California, San Francisco (UCSF) and Sanofi are to launch a new collaboration in diabetes research, focusing on …
Study supports GLP-1 agonists for weight loss
January 10, 2012Research and Development, Sales and Marketing GLP-1, Novo Nordisk, Sanofi, diabetes, lilly
An independent study by academics has concluded that GLP-1 agonist drugs help patients to lose weight – with the effect …
AstraZeneca takes option on new diabetes candidates
December 21, 2011Sales and Marketing AstraZeneca, diabetes
AstraZeneca and Prosidion, a subsidiary of Astellas have signed a deal giving AstraZeneca an exclusive option to acquire two diabetes …
Novo confident on ultra-long acting insulin
December 8, 2011Sales and Marketing Novo Nordisk, diabetes, insulin
Novo Nordisk says a new combination of a long-acting insulin with a short-acting insulin helps patients maintain better control of …
No cancer link with Lantus, says Sanofi
December 7, 2011Sales and Marketing Cancer, Lantus, Sanofi, diabetes, insulin, safety
Sanofi has presented a new meta-analysis which suggests its insulin blockbuster Lantus does not raise the risk of cancer. A …
Onglyza cleared for use with insulin
November 29, 2011Sales and Marketing AstraZeneca, Merck, Onglyza, diabetes, insulin
European regulators have approved a licence extension for Bristol-Myers Squibb and AstraZeneca’s type II diabetes treatment Onglyza. The oral DPP-4 …
GSK diabetes drug fails head-to-head against Victoza
November 16, 2011Sales and Marketing GLP-1, Victoza, albiglutide, diabetes
GlaxoSmithKline’s long-acting diabetes drug albiglutide has failed in a head-to-head trial against Novo Nordisk’s Victoza. Albiglutide is an injectable glucagon-like …
Byetta approved for use with insulin
October 19, 2011Amylin, GLP-1, diabetes, lilly
The FDA has approved the use of Lilly and Amylin’s diabetes treatment Byetta as an add-on therapy to insulin glargine.The …
NICE recommends Lilly’s long-acting Bydureon
October 18, 2011Sales and Marketing Bydureon, NICE, diabetes
NICE has recommended Eli Lilly’s long-acting diabetes drug Bydureon after the failure of oral treatments. Bydureon (exenatide) – a long-acting …
Russian diabetes market to grow to $1.7 billion
October 17, 2011Sales and Marketing Russia, diabetes
Russia’s diabetes market is set be worth $1.7 billion by 2015, according to a new report. Industry analysts Decision Resources’ …
Novo Nordisk’s Victoza launched in China
October 10, 2011Sales and Marketing Byetta, China, Victoza, diabetes
Novo Nordisk’s Victoza is now available in China, one of the fastest growing diabetes markets in the world. Victoza (liraglutide …
Latest content
MHRA approves Romvimza for tenosynovial giant cell tumour
Panthera opens clinical trial site at Keele University
Santen joins inaugural Global Summit for Eye Health as partner
